Toronto Dominion Bank cut its stake in Zoetis Inc (NYSE:ZTS) by 99.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 611 shares of the company’s stock after selling 359,026 shares during the period. Toronto Dominion Bank’s holdings in Zoetis were worth $43,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Hoover Financial Advisors Inc. purchased a new stake in Zoetis in the second quarter valued at $27,000. Lipe & Dalton purchased a new stake in shares of Zoetis in the second quarter valued at about $30,000. Campbell Wealth Management purchased a new stake in shares of Zoetis in the second quarter valued at about $34,000. Lion Street Advisors LLC purchased a new stake in shares of Zoetis in the first quarter valued at about $30,000. Finally, Truvestments Capital LLC purchased a new stake in shares of Zoetis in the first quarter valued at about $33,000. 91.42% of the stock is owned by hedge funds and other institutional investors.
ZTS has been the subject of a number of research reports. Credit Suisse Group reaffirmed a “buy” rating and issued a $147.00 target price on shares of Zoetis in a report on Monday, May 18th. Bank of America increased their price target on shares of Zoetis from $135.00 to $150.00 and gave the stock a “neutral” rating in a report on Monday, July 20th. Citigroup increased their price target on shares of Zoetis from $146.00 to $160.00 and gave the stock a “neutral” rating in a report on Monday, August 10th. G.Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Morgan Stanley increased their price target on shares of Zoetis from $125.00 to $167.00 and gave the stock an “equal weight” rating in a report on Thursday. Ten research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $151.50.
In other news, CEO Kristin C. Peck sold 10,500 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $131.31, for a total value of $1,378,755.00. Following the sale, the chief executive officer now directly owns 43,759 shares in the company, valued at $5,745,994.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,885 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $159.07, for a total transaction of $299,846.95. Following the completion of the sale, the director now owns 4,635 shares in the company, valued at $737,289.45. The disclosure for this sale can be found here. Insiders sold 28,922 shares of company stock worth $4,248,547 over the last quarter. Company insiders own 0.17% of the company’s stock.
ZTS traded up $0.14 on Thursday, hitting $158.72. 22,138 shares of the company were exchanged, compared to its average volume of 1,537,166. The company has a debt-to-equity ratio of 2.46, a quick ratio of 2.60 and a current ratio of 3.47. The business’s fifty day moving average is $147.28 and its 200 day moving average is $134.50. Zoetis Inc has a fifty-two week low of $90.14 and a fifty-two week high of $163.98. The firm has a market capitalization of $76.10 billion, a P/E ratio of 47.07, a price-to-earnings-growth ratio of 4.59 and a beta of 0.80.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.25. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same period in the prior year, the business posted $0.90 earnings per share. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. Analysts forecast that Zoetis Inc will post 3.61 EPS for the current fiscal year.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: QQQ ETF
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.